Last reviewed · How we verify
Neulasta
At a glance
| Generic name | Neulasta |
|---|---|
| Also known as | pegfilgrastim, Neulasta, Pegfilgrastim, Recombinant human granulocyte colony-stimulating factor (G-CSF), Pegylated Granulocyte Colony-Stimulating Factor (PEG-GCSF) |
| Sponsor | Columbia University |
| Target | Granulocyte colony-stimulating factor receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- Allogeneic peripheral blood stem cell transplant
- Chemotherapy-induced neutropenia
Common side effects
- Bone pain
- Pain in extremity
- Leukocytosis
Serious adverse events
- Splenic rupture
- Acute respiratory distress syndrome
- Serious hypersensitivity reactions/anaphylaxis
- Glomerulonephritis
- Thrombocytopenia
- Capillary leak syndrome
- Myelodysplastic syndrome
- Acute myeloid leukemia
- Aortitis
- Sickle cell crisis
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer (PHASE1, PHASE2)
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (PHASE2)
- Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (PHASE2)
- ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neulasta CI brief — competitive landscape report
- Neulasta updates RSS · CI watch RSS
- Columbia University portfolio CI